Two-drug treatment before surgery for early triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two targeted medicines given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can improve outcomes for patients with this type of breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have been diagnosed with triple-negative breast cancer that has not been treated yet and has not spread beyond the breast or nearby lymph nodes.
- Your tumor is a certain size or has spread to lymph nodes, as determined by your doctor.
- You have not had any prior cancer treatment.
- You are in generally good health with adequate organ function.
- You are willing to provide a tumor tissue sample for testing.
- You are not pregnant or breastfeeding and agree to use effective contraception if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial is testing a combination of two targeted therapies for a specific type of triple-negative breast cancer. The goal is to see if adding a second drug improves the effectiveness of the first treatment in slowing the cancer's growth.
This study tests a new combination of two medicines (SHR-A2102 and adebrelimab) given before surgery to treat early-stage triple-negative breast cancer. This approach aims to shrink the tumor and potentially improve the chances of a cure.
This trial tests a new drug, serplulimab, combined with standard chemotherapy (paclitaxel and carboplatin) given before surgery for triple-negative breast cancer. The goal is to see if this combination can shrink tumors more effectively.
This trial is testing whether giving a combination of two medicines before surgery can help shrink or eliminate tumors in people with triple-negative breast cancer (a type of breast cancer that lacks certain receptors). The goal is to see if this approach improves outcomes compared to the usual approach.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.